Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022

SIMPLE SUMMARY: Therapeutic advances in acute myeloid leukemia (AML) are dependent on identifying and targeting the molecular aberrations that drive disease. The European LeukemiaNet (ELN) 2022 guidelines have improved the categorization of AML into distinct molecular subgroups. One of the most nota...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouligny, Ian M., Maher, Keri R., Grant, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340017/
https://www.ncbi.nlm.nih.gov/pubmed/37444402
http://dx.doi.org/10.3390/cancers15133292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340017/
https://www.ncbi.nlm.nih.gov/pubmed/37444402
http://dx.doi.org/10.3390/cancers15133292

Ejemplares similares